- Merck’s Q3 2024 report shows accelerated growth across all sectors, with organic sales up 3.8% to €5.3 billion and EBITDA pre up 16.9% to €1.6 billion.
- Life Science returned to growth, Healthcare showed strong profitability, and Electronics maintained profitable growth.
- Merck confirms its 2024 guidance, expecting sales growth between 2-5% and EBITDA pre growth between 4-10%.
Thu Nov 14 07:02:03 -0000 2024 UTC– Merck accelerated growth in Q3 2024 with all sectors showing sales and earnings increases, confirming guidance for fiscal 2024.
Life Science returned to organic growth, Healthcare had solid sales growth, and Electronics saw profitable growth. Key figures and sector breakdowns are detailed.
Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:
About Lisa
Subscribe to Lisa’s Newsletter today!
Keep Up: Nobot.News Launches Breaking Newsletter
Read more Business News as it happens!
Business